{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:55:24Z","timestamp":1777575324289,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.023","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T10:49:19Z","timestamp":1657450159000},"page":"349-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-5783","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2022.06.023_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jclinepi.2014.12.016","article-title":"Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor","volume":"68","author":"Flacco","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.ejca.2022.06.023_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.mayocp.2015.05.006","article-title":"Hard-wired bias: how even double-blind, randomized controlled trials can Be skewed from the start","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.ejca.2022.06.023_bib3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and drug administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.06.023_bib4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1470-2045(18)30501-1","article-title":"Choice of control group in randomised trials of cancer medicine: are we testing trivialities?","volume":"19","author":"Tao","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.023_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44770","article-title":"Reporting of physicians' or investigators' choice of treatment in oncology randomized clinical trials","volume":"5","author":"Olivier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ejca.2022.06.023_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2022.06.023_bib7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2013.53.0204","article-title":"Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients","volume":"32","author":"Prasad","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.023_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38793","article-title":"Anticancer drugs approved by the US Food and drug administration from 2009 to 2020 according to their mechanism of action","volume":"4","author":"Olivier","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"15","key":"10.1016\/j.ejca.2022.06.023_bib9","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.06.023_bib10","unstructured":"National Comprehensive Cancer Network. Hematopoietic Growth Factors (Version 1.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed February 20, 2022."},{"issue":"10","key":"10.1016\/j.ejca.2022.06.023_bib11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","article-title":"Fixed dosing of monoclonal antibodies in oncology","volume":"22","author":"Hendrikx","year":"2017","journal-title":"Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2022.06.023_bib12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"10126","key":"10.1016\/j.ejca.2022.06.023_bib13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.023_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2020.4811","article-title":"Drug approvals in hepatocellular carcinoma\u2014filling the nonexistent gap?","volume":"7","author":"Desai","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10183","key":"10.1016\/j.ejca.2022.06.023_bib15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.023_bib16","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.tranon.2021.101248","article-title":"Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): four design features in the ASCENT trial potentially favored the experimental arm","volume":"15","author":"Olivier","year":"2022","journal-title":"Transl Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:48Z","timestamp":1760733528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":16,"alternative-id":["S0959804922003744"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}